BioWorld

June 25, 2004

Amgen Submits Fast-Track Palifermin BLA In Mucositis

Amgen Inc. is requesting U.S. regulatory approval under fast-track guidelines for palifermin, a first-in-class investigational compound for oral mucositis. (BioWorld Today) Read More

FDA To Cardiome: More Data Needed To Clear Oxypurinol

Biogen Idec Forms Parkinson's Deal With Vernalis For $100M

Rejuvenon's $37M Financing To Support Cachexia Product

Anidulafungin Fallout: Vicuron Cutting Expenses, Head Count

Generex Receiving $30M Via Sejong Oralin Licensing Deal

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...